COMPANY

Adverum Biotechnologies

Adverum Biotechnologies is listed on ClinicalTrials.gov as the lead sponsor of 11 studies; the most recently updated is “Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)” (Phase 3, recruiting), in Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD. From public records Source · Oct 12, 2026

Keywords: Neovascular Age-Related Macular Degeneration Wet AMD Wet Age-related Macular Degeneration Diabetic Macular Edema Diabetic Retinopathy Alpha-1 Antitrypsin Deficiency Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD Friedreich's Ataxia ADVM-022 Ixo-vec ADVM-043

Profile checked Oct 10, 2026

11Trials (company is sponsor)

Timeline

Jun 2, 2026 Trial start Phase 2: Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration source ↗
Mar 16, 2026 Trial start Phase 3: Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) source ↗
Feb 28, 2025 Trial start Phase 3: Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration source ↗
Aug 23, 2022 Trial start Phase 2: Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] source ↗
Aug 10, 2022 Trial start —: Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT) source ↗
Dec 14, 2020 Trial start —: Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT] source ↗
May 28, 2020 Trial start Phase 2: ADVM-022 Intravitreal Gene Therapy for DME source ↗
Dec 27, 2018 Trial start —: Long-Term Follow-up Study of ADVM-043 source ↗
Nov 14, 2018 Trial start Phase 1: ADVM-022 Intravitreal Gene Therapy for Wet AMD source ↗
Nov 28, 2017 Trial start Phase 1/Phase 2: Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency source ↗
2016-07 Trial start Not phased (device or behavioral study): A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study) source ↗

Upcoming milestones

Dec 22, 2026 (ESTIMATED) · Phase 3 · Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration · NCT06856577
Nov 15, 2027 (ESTIMATED) · Phase 3 · Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) · NCT07482176
Jun 26, 2030 (ESTIMATED) · · Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT] · NCT04645212
2031-06 (ESTIMATED) · Phase 2 · Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration · NCT07630649

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 11

Record	Title	Phase	Status	Start	Primary completion
NCT07482176	Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)	Phase 3	Recruiting	Mar 16, 2026	Nov 15, 2027 (estimated)
NCT07630649	Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration	Phase 2	Recruiting	Jun 2, 2026	2031-06 (estimated)
NCT06856577	Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration	Phase 3	Active, not recruiting	Feb 28, 2025	Dec 22, 2026 (estimated)
NCT04645212	Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]	Not listed	Active, not recruiting	Dec 14, 2020	Jun 26, 2030 (estimated)
NCT05536973	Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]	Phase 2	Active, not recruiting	Aug 23, 2022	Aug 26, 2024 (actual)
NCT04418427	ADVM-022 Intravitreal Gene Therapy for DME	Phase 2	Completed	May 28, 2020	Nov 22, 2022 (actual)
NCT05607810	Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)	Not listed	Active, not recruiting	Aug 10, 2022	2026-04 (estimated)
NCT03804021	Long-Term Follow-up Study of ADVM-043	Not listed	Completed	Dec 27, 2018	Dec 6, 2021 (actual)
NCT02168686	Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency	Phase 1/Phase 2	Completed	Nov 28, 2017	Aug 29, 2019 (actual)
NCT03748784	ADVM-022 Intravitreal Gene Therapy for Wet AMD	Phase 1	Completed	Nov 14, 2018	Jun 22, 2022 (actual)
NCT02840669	A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)	Not phased (device or behavioral study)	Completed	2016-07	2018-06 (actual)